Illumina launches ultrasensitive sequencing for detecting trace tumor DNA in cancer research.

Illumina has introduced an early access program for a new ultrasensitive sequencing workflow designed to detect very low levels of circulating tumor DNA (ctDNA) in plasma samples. This technology uses duplex chemistry to analyze both DNA strands, enhancing detection accuracy to as low as 2.5 parts per million with minimal sample input. It supports whole-genome studies of molecular residual disease (MRD), aiding researchers in tracking tumor evolution and recurrence with greater sensitivity. The program, expected to ship kits in early 2027, aims to simplify lab workflows and accelerate MRD research globally.

As of Nov 09, 2026 21:11 WIB, Illumina, Inc. (ILMN) shares are trading at USD 217.22 on Pluang, showing a 1.92% increase in the last day. The company holds a market capitalization of $32.23 billion and an enterprise value of $33.20 billion, reflecting solid investor interest. This trading activity coincides with Illumina's advancement in molecular residual disease research through its new ultrasensitive sequencing technology.